Locations:
SearchAdvertisement
Lower toxicity than conventional chemo
Groundbreaking study paves way for targeted therapy
Gene signatures differentiate clinical response
10-year outcomes favor autologous over implant
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Initial study results are encouraging
Higher doses don’t mean higher toxicity
New system better predicts patient outcomes
May help identify patients for immunotherapy
Second (or third) time’s a charm in reducing splenomegaly and other symptoms
Using data science to identify intrinsic patterns in cancer data
Advertisement
Advertisement